Business
Cardio Diagnostics Holdings, Inc Partners with Ascension Borgess Hospital’s Heart Attack Prevention Clinic on Coronary Artery Disease Study
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven Epi+Gen CHD and PrecisionCHD tests will be leveraged in a research study led by Dr. Vishal Gupta, a cardiologist and the head of the Heart Attack Prevention Clinic at Ascension Borgess.\n\n\nAs the burden of cardiovascular disease grows globally, advanced coronary artery disease (CAD) detection tools are needed to proactively identify CAD before events occur. Dr. Gupta’s study aims to determine which new technologies should be routinely used to optimize the detection of asymptomatic coronary artery disease. With this study, Dr. Gupta and his team aim to identify effective coronary artery disease detection technologies to implement as the standard of care for patients cared for at the Heart Attack Prevention Clinic.\n\n\nCardio Diagnostics' epigenetic and genetic heart disease tests will be incorporated into an ongoing multi-year study alongside other CAD detection methods. An innovative cardiologist for decades, Dr. Gupta, who has been credited with advancing personalized cardiovascular medicine, is board-certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology.\n\n\n“Early and more precise detection of coronary artery disease coupled with actionable insights can save lives through preventive care before heart attacks occur,” said Dr. Gupta. “This research will help us determine which diagnostic tools offer value in finding hidden heart disease in asymptomatic patients.”\n\n\nThe costs associated with cardiovascular disease are substantial. According to the American Heart Association, cardiovascular disease direct medical costs and indirect costs will top $1 trillion by 2035 in the United States alone.\n\n\nEarly detection and prevention of cardiovascular disease using advanced technologies like Cardio Diagnostics' AI-powered tests, PrecisionCHD and Epi+Gen CHD, may significantly reduce costs. Preventing just one heart attack avoids around $24,000 in direct medical costs. By enabling more precise assessments and earlier interventions, these innovative diagnostic tests may prevent costly and potentially deadly heart attacks before they happen.\n\n\n“We are excited to support Dr. Gupta’s groundbreaking research i...